『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=236512)

EID=236512EID:236512, Map:0, LastModified:2012年8月29日(水) 15:15:07, Operator:[大家 隆弘], Avail:TRUE, Censor:0, Owner:[[部長]/[徳島大学.病院.中央診療施設等.リハビリテーション部]], Read:継承, Write:継承, Delete:継承.
種別 (必須):
言語 (必須): 英語 [継承]
招待 (推奨):
審査 (推奨):
カテゴリ (推奨):
共著種別 (推奨):
学究種別 (推奨):
組織 (推奨):
著者 (必須): 1. (英) Yoh Kousei (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
2.髙田 信二郎
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
3. (英) Yoshimura Noriko (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
4. (英) Hashimoto Jun (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
題名 (必須): (英) Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.  (日)    [継承]
副題 (任意):
要約 (任意): (英) This study evaluated the clinical efficacy of treatment with oral risedronate (17.5 mg once daily) for 8 weeks in 11 Japanese patients with Paget's disease of bone (PDB). Risedronate suppressed the excessive bone turnover associated with PDB and improved several biochemical markers, including serum alkaline phosphatase (ALP), serum bone-specific ALP (BALP), urinary deoxypyridinoline (DPD), and urinary cross-linked N-telopeptide of type 1 collagen (NTX). These markers began to decrease within about 2 weeks after the initiation of treatment in most patients, and the response persisted for up to 40 weeks after the cessation of treatment. Risedronate reduced pain by week 24 in most patients. According to quantitative bone scintigraphy, the lesion with the highest radioisotope (RI) uptake showed a decrease of uptake from 12.7 +/- 6.8 to 6.0 +/- 2.3 (mean +/- SD) in week 24, although each lesion of patients with polyostotic disease had a different scintigraphic response. Overall, risedronate at a dose of 17.5 mg once daily was well tolerated by patients with PDB, even though the dosage was seven times higher than that approved for the treatment of osteoporosis in Japan (2.5 mg once daily). In conclusion, treatment with high-dose risedronate for 8 weeks resulted in clinically significant and sustained improvement of biochemical markers of bone turnover for 48 weeks in patients with PDB, and this improvement was associated with a decrease of RI uptake by Paget's bone lesions and with reduced pain.  (日)    [継承]
キーワード (推奨): 1. (英) Adult (日) (読) [継承]
2. (英) Aged (日) (読) [継承]
3. (英) Aged, 80 and over (日) (読) [継承]
4. (英) Bone Density Conservation Agents (日) (読) [継承]
5. (英) Etidronic Acid (日) (読) [継承]
6. (英) Female (日) (読) [継承]
7. (英) Humans (日) (読) [継承]
8. (英) Male (日) (読) [継承]
9. (英) Middle Aged (日) (読) [継承]
10. (英) Osteitis Deformans (日) (読) [継承]
11. (英) Treatment Outcome (日) (読) [継承]
発行所 (推奨):
誌名 (必須): Journal of Bone and Mineral Metabolism ([Springer-Verlag])
(pISSN: 0914-8779, eISSN: 1435-5604)

ISSN (任意): 1435-5604
ISSN: 0914-8779 (pISSN: 0914-8779, eISSN: 1435-5604)
Title: Journal of bone and mineral metabolism
Title(ISO): J Bone Miner Metab
Supplier: Springer Online Journal Archive
Publisher: Springer
 (NLM Catalog  (医中誌Web  (Scopus  (CrossRef (Scopus information is found. [need login])
[継承]
[継承]
(必須): 28 [継承]
(必須): 4 [継承]
(必須): 468 476 [継承]
都市 (任意):
年月日 (必須): 西暦 2010年 2月 24日 (平成 22年 2月 24日) [継承]
URL (任意):
DOI (任意): 10.1007/s00774-009-0152-9    (→Scopusで検索) [継承]
PMID (任意): 20179977    (→Scopusで検索) [継承]
NAID (任意):
WOS (任意):
Scopus (任意):
評価値 (任意):
被引用数 (任意):
指導教員 (推奨):
備考 (任意): 1.(英) Article.Affiliation: Department of Orthopedic Surgery, Sasayama Hospital, Hyogo Medical College, 75 Yamauchi-cho, Sasayama 669-2337, Japan. k-yoh@hyo-med.ac.jp  (日)    [継承]
2.(英) Article.PublicationTypeList.PublicationType: Clinical Trial, Phase III  (日)    [継承]
3.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]
4.(英) Article.PublicationTypeList.PublicationType: Multicenter Study  (日)    [継承]
5.(英) Article.PublicationTypeList.PublicationType: Research Support, Non-U.S. Gov't  (日)    [継承]

標準的な表示

和文冊子 ● (種別) : Kousei Yoh, Shinjiro Takata, Noriko Yoshimura and Jun Hashimoto : Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone., Journal of Bone and Mineral Metabolism, Vol.28, No.4, 468-476, (発行所), (都市), Feb. 2010.
欧文冊子 ● (種別) : Kousei Yoh, Shinjiro Takata, Noriko Yoshimura and Jun Hashimoto : Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone., Journal of Bone and Mineral Metabolism, Vol.28, No.4, 468-476, (発行所), (都市), Feb. 2010.

関連情報

Number of session users = 0, LA = 1.56, Max(EID) = 383938, Max(EOID) = 1026856.